Peptide receptor imaging technology (PRIT) can be used for peptide receptor radionuclide diagnosis and therapy (PRRT). The principle is as follows: target is called “Lock” (referring to tumor cells), and its tissue is characterized by highly expressed receptors on the surface; Ligand is called “Key” (referring to somatostatin analogues), such as octreotide; Linker is the connector between ligands and chelating agents, and the carrier between “Navigator” and “warhead”; Chelator is a bifunctional chelating agent, called “reporter imaging body”, which can effectively capture radioisotopes, such as F18 or Ga68, which is conducive to the imaging of PET/CT and PET/MR and the specific orientation of cancer cells. This technology can be vividly compared to the targeted removal of cancer cells with a precision guided “cruise missile”. Cancer cells are the target to be destroyed. The ligand is a “GPS Navigator”. The chelating agent is bound with radioisotopes with “high-energy imaging or treatment bomb”, such as Y90 or Lu177. After a number of clinical trials, this technology can now find cancer cells with a minimum size of 2mm. It is recognized as the most accurate radionuclide targeted personalized treatment in the world.